Palatin Technologies, Inc. Common Stock (PTN)

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Palatin Technologies Scores Triple Win with Breakthrough Results in Obesity, Colitis, and Kidney Disease

Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing.

Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)

Palatin's PL8177 showed promising ulcerative colitis trial results, with strong clinical response rates. FDA granted orphan status to its obesity drug PL7737.

Unusual volume stocks in Friday's session

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions

PTN stock results show that Palatin Techs missed analyst estimates for earnings per share the third quarter of 2024.

The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically significant efficacy in pain reduction and secondary symptoms. PL9643 demonstrates superior safety and tolerability compared to existing treatments, promising a differentiated solution in the $6.11 billion dry eye disease market.

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

Palatin Technologies' results from PL9643 MELODY-1 Phase 3 trial for dry eye disease. The co-primary endpoints and secondary endpoints did not reach statistical significance.